Abeona Therapeutics (ABEO) – Company Press Releases
-
Abeona Therapeutics Provides Regulatory Update on Pz-cel
-
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
-
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
-
Abeona Therapeutics Announces $50 Million Credit Facility
-
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
-
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
-
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
-
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
-
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
-
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
-
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
-
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
-
Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
-
Abeona Therapeutics Joins Rare Disease Company Coalition
-
Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101
-
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
-
Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023
-
Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
-
Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
-
Abeona Therapeutics Reports First Quarter 2023 Financial Results
-
Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting
-
Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
-
Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
-
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
-
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
-
Abeona Therapeutics Announces New Employee Inducement Grants
-
Abeona Therapeutics Announces New Employee Inducement Grants
-
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
-
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
-
Abeona Therapeutics Announces Update on AAV Ophthalmology Program
-
Abeona Therapeutics Announces Update on AAV Ophthalmology Program
-
Abeona Therapeutics Reports Third Quarter 2022 Financial Results
-
Abeona Therapeutics Reports Third Quarter 2022 Financial Results
-
Abeona Therapeutics Announces $35 Million Private Placement Financing
-
Abeona Therapeutics Announces $35 Million Private Placement Financing
-
Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
-
Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
-
Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
-
Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
-
Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
-
Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
-
Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
-
Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
Back to ABEO Stock Lookup
